Ivonescimab Shows Survival Benefit in NSCLC

The investigational bispecific antibody ivonescimab demonstrated a significant improvement in overall survival (OS) for patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC) when compared to the single-agent immunotherapy pembrolizumab (Keytruda). This finding comes from an updated analysis of the Phase 3 INTELLECT-01 trial, presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial enrolled 1,094 patients with previously untreated, advanced NSCLC who had a PD-L1 tumor proportion score of 1% or higher. Patients were randomized to receive either ivonescimab plus chemotherapy or pembrolizumab plus chemotherapy. The primary endpoint of progression-free survival (PFS) was previously reported to be met, showing a statistically significant and clinically meaningful improvement for the ivonescimab arm. The updated OS data further strengthens the potential of ivonescimab as a new treatment option. Ivonescimab is designed to simultaneously target PD-L1 and VEGF, two key pathways involved in tumor growth and immune evasion. By blocking both targets, it aims to enhance anti-tumor immunity and reduce tumor vascularization. This dual-action mechanism is hypothesized to be more effective than targeting a single pathway. The study's design involved a rigorous evaluation of survival outcomes, a critical measure of treatment efficacy in oncology. The INTELLECT-01 trial is a pivotal study for ivonescimab, and its positive results are expected to support regulatory submissions. The bispecific antibody is being developed by Akeso Biopharma. Pembrolizumab, marketed by Merck & Co. as Keytruda, is a well-established checkpoint inhibitor that has revolutionized the treatment of various cancers, including NSCLC, by blocking the PD-1 pathway. The comparison against this standard of care highlights the potential superiority of the bispecific approach in a specific patient population. Non-small cell lung cancer remains a leading cause of cancer-related deaths worldwide, and the development of novel therapies that can improve survival rates is of paramount importance. The PD-L1 expression level is a crucial biomarker in NSCLC, as it predicts response to PD-1/PD-L1 inhibitors. Patients with high PD-L1 expression are more likely to benefit from immunotherapy. The inclusion of this stratification in the INTELLECT-01 trial ensures that the efficacy of ivonescimab is evaluated in a population most likely to respond to immune-based therapies. The updated OS data from INTELLECT-01 is anticipated to be a significant factor in the ongoing discussion about the role of bispecific antibodies in the treatment landscape of advanced NSCLC, potentially offering a new standard of care for patients with PD-L1-positive disease.